Okyanos Heart Institute CEO Matt Feshbach To Speak On Panel At STEMSO
Okyanos Heart Institute, whose mission it is to bring a new standard of care and a better quality of life to patients with coronary artery disease using adult stem cell therapy, announces CEO Matt Feshbach will present at the International Stem Cell Society (STEMSO) Conference. He will join a panel to discuss the opportunities available through the new Stem Cell Research and Therapy Act. The conference will be held at the Grand Lucayan Resort in Freeport, Grand Bahamas, February 19-22, 2014. The panel discussion will be Friday, February 21 from 8:45 – 9:45 a.m.
The conference, titled “Bridging the Gap: Research to Point of Care,” brings together medical scientists, clinicians, regulatory experts, and investors to discuss progress in the field of research and clinical protocols and the process of taking promising therapies to fight chronic disease to market in a responsible manner.
Friday opening remarks will be delivered by Ian Rolle, President of Grand Bahama Port Authority from 8:30 a.m. to 8:45 a.m. followed by the panel presentation until 9:45 a.m. which, in addition to Rolle will include Feshbach, Mitchell Fuerst, Esq., managing partner, Fuerst, Ittleman, David and Joseph. The panel will be moderated by Arthur K. Parris, Jr. of Parris Whittaker.
“With the passing of the Bahamas Stem Cell Research and Therapy Act, which requires high standards of patient safety and care, we believe the Bahamas is an ideal location to bring internationally-approved, adult stem cell technology to patients with unmet medical needs such as chronic coronary artery disease (CAD),” says Feshbach. “I am pleased to discuss the opportunities available in the Bahamas with investors, doctors and other stakeholders interested in making the Bahamas a world-class destination for adult stem cell therapy.”
“The STEMSO 2014 Conference in Freeport, Grand Bahama poses a unique opportunity for medical organizations which focus on adult stem cell-based medical treatments,” states Douglas Hammond, president of STEMSO. “This conference will provide companies looking to expand their research or clinical practices to offshore locations many good reasons to choose the Bahamas. Those attending will be able to network and view the most advanced research and clinical protocols utilizing autologous and allogeneic stem cells in the world today.”
The complete agenda can be found on the organization’s website at www.stemso.org. Other speakers include stem cell researchers, scientists and practitioners from around the world with leading discoveries in the field, and investors in the healthcare space.
Registration is open for attending and exhibiting on STEMSO’s website.
ABOUT OKYANOS HEART INSTITUTE: (Oh – key – AH – nos)
Based in Freeport, The Bahamas, Okyanos Heart Institute’s mission is to bring a new standard of care and a better quality of life to patients with coronary artery disease using cardiac stem cell therapy. Okyanos adheres to U.S. surgical center standards and is led by Chief Medical Officer Howard T. Walpole Jr., M.D., M.B.A., F.A.C.C., F.S.C.A.I. Okyanos Treatment utilizes a unique blend of stem and regenerative cells derived from one’s own adipose (fat) tissue. The cells, when placed into the heart via a minimally-invasive procedure, can stimulate the growth of new blood vessels, a process known as angiogenesis. Angiogenesis facilitates blood flow in the heart, which supports intake and use of oxygen (as demonstrated in rigorous clinical trials such as the PRECISE trial). The literary name “Okyanos,” the Greek god of rivers, symbolizes restoration of blood flow. For more information, go to http://www.okyanos.com/.